Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler is GMP-Ready and Operational
September 19, 2024 07:00 ET
|
Lifecore Biomedical, Inc.
Installation and Qualification Successfully Completed for Closed-System Filler for Pre-Filled Syringes, Vials, and Cartridges Offers State-of-the-Art Speed and Aseptic Isolation Required for...
Arqit Quantum Inc. Announces 25:1 Reverse Share Split
September 19, 2024 07:00 ET
|
Arqit
LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Arqit Quantum Inc. (Nasdaq: ARQQ) (“Arqit” or the “Company”), a leader in quantum safe encryption, today announces that, following approval by the...
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
September 19, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
MoneyHero Group Reports Second Quarter 2024 Results
September 19, 2024 07:00 ET
|
MoneyHero Limited
MoneyHero Group Reports Second Quarter 2024 Results
Nayax to Partner With Five Star's Feeding the Future Charitable Golf Tournament on September 23, 2024
September 19, 2024 07:00 ET
|
Nayax Ltd.
Nayax is proud to be a sponsor of Feeding the Future’s Golf Classic for the fourth consecutive year.
Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease
September 19, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
September 19, 2024 07:00 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
September 19, 2024 07:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
September 19, 2024 07:00 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
FactSet Reports Results for Fourth Quarter 2024
September 19, 2024 07:00 ET
|
FactSet Research Systems Inc.
Q4 GAAP revenues of $562.2 million, up 4.9% from Q4 2023.Organic Q4 ASV plus professional services of $2,272.8 million, up 4.8% year over year.Q4 GAAP operating margin of 22.7%, up approximately 110...